Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

ClinicalTrials.gov ID: NCT07011667

Public ClinicalTrials.gov record NCT07011667. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.

Study identification

NCT ID
NCT07011667
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
609 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2, 2025
Primary completion
Feb 28, 2027
Completion
Oct 16, 2028
Last update posted
Jul 23, 2026

2025 – 2028

United States locations

U.S. sites
46
U.S. states
19
U.S. cities
44
Facility City State ZIP Site status
FDRC Costa Mesa California 92627
Linda Vista Health Care Ctr San Diego California 92111
Diablo Clinical Research, Inc. Walnut Creek California 94598
Northeast Research Institute Fleming Island Florida 32003
Jacksonville Ctr For Clin Res Jacksonville Florida 32216
South Broward Research LLC Miramar Florida 33027
Florida Inst For Clin Res LLC Orlando Florida 32825
Oviedo Medical Research, LLC Oviedo Florida 32765
Center for Diab,Obes & Metab Pembroke Pines Florida 33024
Hope Clin Res & Wellness Conyers Georgia 30094
Endocrine Research Solutions Roswell Georgia 30076
Great Lakes Clinical Trials Chicago Illinois 60640
Endeavor Health Skokie Illinois 60077
Evanston Premier Hlthcr Res Skokie Illinois 60077
Midwest Inst For Clin Res Indianapolis Indiana 46260
Iowa Diab & Endo Res Center West Des Moines Iowa 50266
Northern Pines Hlth Ctr, PC Buckley Michigan 49620
StudyMetrix Research LLC City of Saint Peters Missouri 63303
Amicis Centers of Clinical Research St Louis Missouri 63128
Mercury Str Med Grp, PLLC Butte Montana 59701
Southgate Medical Group, LLP West Seneca New York 14224
Great Lakes Medical Research Westfield New York 14787
University of North Carolina Chapel Hill North Carolina 27514
Medication Mgmnt, LLC_Grnsboro Greensboro North Carolina 27405
PharmQuest Life Sciences LLC Greensboro North Carolina 27408
Accellacare_NC Raleigh North Carolina 27609
Piedmont Healthcare/Research Statesville North Carolina 28625
Accellacare Wilmington North Carolina 28401
New Venture Medical Research Wadsworth Ohio 44281-9236
Lynn Institute of Norman Norman Oklahoma 73072
Clinical Res Collaborative Cumberland Rhode Island 02864
Coastal Carolina Res Ctr North Charleston South Carolina 29405
Hillcrest Clinical Research Simpsonville South Carolina 29681-1538
Spartanburg Medical Research Spartanburg South Carolina 29303
Holston Medical Group Kingsport Tennessee 37660
Clinical Research Associates Nashville Tennessee 37203
Amarillo Medical Specialists Amarillo Texas 79124
Velocity Clin Res, Dallas Dallas Texas 75230
PlanIt Research, PLLC Houston Texas 77079
Radiance Clinical Research Lampasas Texas 76550
DCOL Ctr for Clin Res Longview Texas 75605
Northeast Clinical Research of San Antonio Schertz Texas 78154
Washington Cntr Weight Mgmt Arlington Virginia 22206
Health Res of Hampton Roads Newport News Virginia 23606
Selma Medical Associates Winchester Virginia 22601-3834
Rainier Clin Res Ctr Inc Renton Washington 98057

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07011667, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 23, 2026 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07011667 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →